title: Risk stratification of prostate cancer 2016.
abstract: Prostate cancer is a common malignancy in men, but its management is fraught with controversy owing to its variable biologic and clinical behavior. Despite evidence that PSA screening reduces prostate cancer specific metastasis and death, it has not gained acceptance by various health authorities. Nevertheless, recent advances in biomarker development potentially address many of the shortcomings of routine PSA testing alone, including improved specificity for the detection of clinically significant cancer, optimized risk stratification to aid clinical management decisions, and discovery of genetic variants that may guide optimized therapy of advanced disease.
authors.affiliation: a Bing Professor of Urologic Research, Department of Urology , Institute of Urologic Oncology, Geffen School of Medicine at UCLA , Los Angeles , CA , USA.
authors.forename: Robert E
authors.initials: RE
authors.lastname: Reiter
mesh_terms: D000951:Antigens, Neoplasm / Q000235:genetics / Q000652:urine; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics*; D001706:Biopsy; D042241:Early Diagnosis; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D060787:Neoplasm Grading; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood / Q000235:genetics; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D011944:Receptors, Androgen / Q000235:genetics / Q000378:metabolism; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D011944:Receptors, Androgen; C479341:prostate cancer antigen 3, human; D017430:Prostate-Specific Antigen
keywords: 4K score; Decipher; PHI; fPSA; mpMRI; oncotype Dx